Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2018-99-115706

Published: 2018

Journal Articles

Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies

Veronika Kozlova, Aneta Ledererova, Michael Doubek, MD PhD, Jiri Mayer, MD, Sarka Pospisilova, Michal Smida, PhD MSc

Blood (2018) 132 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2018-99-118669

Published: 2018

Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 3828.

https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828

Published: 2017

Journal Articles

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Shariful Islam, MS, Wenqing Qi, PhD, Carla Morales, B.S., Laurence Cooke, M.S., Manjari Pandey, MD, Catherine M. Spier, MD, Daruka Mahadevan, MD PhD

Blood (2016) 128 (22): 5397.

https://doi.org/10.1182/blood.V128.22.5397.5397

Published: 2016

Journal Articles

Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine

Maneka Perinpanayagam, PhD, Anna Kovalchuk, Yibing Ruan, PhD, Sungmyung Kang, Aarthi Jayanthan, Olga Kovalchuk, Jessica Boklan, MD, Aru Narendran, MD PhD

Blood (2014) 124 (21): 983.

https://doi.org/10.1182/blood.V124.21.983.983

Published: 2014

Journal Articles

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Annette E Hay, MB ChB, Alli Murugesan, PhD, Ashley M. DiPasquale, BSc, Tom Kouroukis, MD MSc, FRCPC, Irwindeep Sandhu, MD FRCPC, Vishal Kukreti, MD, Nizar J Bahlis, MD, Johan Lategan, MD, Donna E. Reece, MD, John F. Lyons, PhD, Joana Sederias, MSc, Jean Powers, MSc, Hao Xu, MSc, Lesley K. Seymour, MD PhD FRCP (C), Anthony Reiman, MD

Blood (2014) 124 (21): 5734.

https://doi.org/10.1182/blood.V124.21.5734.5734

Published: 2014

Journal Articles

A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia

Amir T. Fathi, MD, Seth A. Wander, MD PhD, Traci M. Blonquist, Karen K. Ballen, MD, Eyal C. Attar, MD, Steven L. McAfee, MD, Yi-Bin Chen, MD, Timothy A. Graubert, MD, Andrew M. Brunner, MD, Christelle Joseph, Ashley M. Perry, Meghan Burke, Regina Silver, Aura Y. Ramos, Christine Connolly, Donna S. Neuberg, ScD, Philip C. Amrein, MD

Blood (2014) 124 (21): 119.

https://doi.org/10.1182/blood.V124.21.119.119

Published: 2014

Journal Articles

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib

Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 5141.

https://doi.org/10.1182/blood.V122.21.5141.5141

Published: 2013

Journal Articles

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Kam Cheung, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy, Mary K Stanton, Tammy L Bush, Richard L Kendall, Robert Radinsky, Steve Abella, Peter C Pieslor, Gregory Friberg, Angela Coxon, Erick Gamelin, Marc Payton

Blood (2013) 122 (21): 3823.

https://doi.org/10.1182/blood.V122.21.3823.3823

Published: 2013

Journal Articles

Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Keith Stewart, MBChB, Ravi Vij, MD, Jacob P. Laubach, MD, Craig C. Hofmeister, MD, Rachel Hagerty, Amylou C. Dueck, PhD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 1859.

https://doi.org/10.1182/blood.V120.21.1859.1859

Published: 2012

Journal Articles

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 1333.

https://doi.org/10.1182/blood.V120.21.1333.1333

Published: 2012

Journal Articles

Bortezomib Is Effective for Down Regulation of Gene Transcriptions Specifically Expressed in Clonogenic Myeloma Side Population Cells

Miho Nara, MD, Hiroyuki Tagawa, MD, PhD, Kazuaki Teshima, MD, Atsushi Watanabe, MD, PhD, Mitsugu Ito, MD, Atsushi Kitabayashi, MD, PhD, Masaaki Kume, MD, PhD, Yoshiaki Hatano, MD, PhD, Shinsuke Iida, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2012) 120 (21): 3939.

https://doi.org/10.1182/blood.V120.21.3939.3939

Published: 2012

Journal Articles

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

Ya-Ping Chen, Hui-Ju Lin, Kung-Chao Chang, Jiann-Shiuh Chen, Ming-Ying Tsai, Liang-Yi Hung, Tsai-Yun Chen

Blood (2012) 120 (21): 4907.

https://doi.org/10.1182/blood.V120.21.4907.4907

Published: 2012

Journal Articles

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Anupam Verma, MD, J. Kimble Frazer, MD, PhD, Alesia Trakhimets, William Heaton, Jared Bearrs, Steven Warner, PhD, David Bearrs, PhD, Sunil Sharma, MD

Blood (2011) 118 (21): 1519.

https://doi.org/10.1182/blood.V118.21.1519.1519

Published: 2011

Journal Articles

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Shaun R Wilson, MBChB, MRCPCH, Victoria J Weston, PhD, Tatjana Stankovic, MD, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1509.

https://doi.org/10.1182/blood.V118.21.1509.1509

Published: 2011

Journal Articles

Combined Inhibition of Janus and Aurora Kinase Effectively Suppresses Proliferation of JAK2 V617F-expressing Cells

Karoline Gäbler, Catherine Rolvering, Valérie Palissot, PhD, Guy J. Berchem, MD, Iris Behrmann, PhD, Claude Haan, PhD

Blood (2011) 118 (21): 2813.

https://doi.org/10.1182/blood.V118.21.2813.2813

Published: 2011

Journal Articles

A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy

Qiang Jeremy Wen, MD, PhD, Serena Silver, PhD, Tim Lewis, PhD, Sridevi Ponduru, MBBS, PhD, Vlado Dancik, phd, Ben Goldenson, Mark Bray, Anne Carpenter, PhD, Paul Clemons, PhD, David Root, phd, Andrew Stern, phd, Robert Gould, phd, John Crispino, PhD

Blood (2010) 116 (21): 89.

https://doi.org/10.1182/blood.V116.21.89.89

Published: 2010

Journal Articles

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3 -ITD Positive AML In Vitro and In Vivo

Andrew S Moore, Amir Faisal, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Florence I Raynaud, Paul Workman, Andrew DJ Pearson, Julian Blagg, Suzanne A Eccles, Spiros Linardopoulos

Blood (2010) 116 (21): 3289.

https://doi.org/10.1182/blood.V116.21.3289.3289

Published: 2010

Journal Articles

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia

Jennifer E Podesta, Melanie J Griffin, Richard Sugar, Matthew S Squires, Alan Boddy, Spiros Linardopoulos, Andrew DJ Pearson, Andrew S Moore

Blood (2010) 116 (21): 1818.

https://doi.org/10.1182/blood.V116.21.1818.1818

Published: 2010

Journal Articles

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Thomas P. Miller, MD, Matthew S Squires, PhD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3930.

https://doi.org/10.1182/blood.V116.21.3930.3930

Published: 2010

NARROW

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Bortezomib Is Effective for Down Regulation of Gene Transcriptions Specifically Expressed in Clonogenic Myeloma Side Population Cells

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Combined Inhibition of Janus and Aurora Kinase Effectively Suppresses Proliferation of JAK2 V617F-expressing Cells

A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3 -ITD Positive AML In Vitro and In Vivo

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only